Skip to main content

Protalix BioTherapeutics, Inc.

PLX
Exchange
NYSE
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001006281

No open-market purchases or sales by Protalix BioTherapeutics, Inc. insiders were filed in the last 90 days; 101 institutions reported holding it in 13F filings for Q2 2026, worth $33.7M in total; no superinvestor holds it.

Q3 2025 vs. Q2 2025

How the institutions holding Protalix BioTherapeutics, Inc. changed between Q2 2025 and Q3 2025.

All holders in Q3 2025All holders in Q2 2025

13F holders of PLX: Q2 2025 compared with Q3 2025
MeasureQ2 2025Q3 2025Change
Holders6377+14
Shares11.9M13.9M+2.02M (+17.0%)
Value$17.6M$30.9M+$13.3M (+75.4%)

New holders (17)

Institutions that held Protalix BioTherapeutics, Inc. at the end of Q3 2025 but not at the end of Q2 2025.

Institutions new to PLX in Q3 2025
InstitutionSharesValue% of portfolio
Opaleye Management Inc.2,580,556$5.73M0.81%
Main Street Financial Solutions, LLC129,100$286.6K0.02%
Deutsche Bank AG65,617$145.7K0.00%
State of Wyoming39,018$86.6K0.01%
Citadel Advisors LLC37,306$82.8K0.00%
Manufacturers Life Insurance Company, The24,054$53.4K0.00%
Virtu Financial LLC16,530$37.0K0.00%
Kestra Advisory Services, LLC11,000$24.4K0.00%
Two Sigma Advisers, LP10,300$22.9K0.00%
LPL Financial LLC10,291$22.8K0.00%
Russell Investments Group, Ltd.7,465$16.6K0.00%
Simplex Trading, LLC2,942$6.00K0.00%
FMR LLC438$9720.00%
SRS Capital Advisors, Inc.296$6580.00%
The PNC Financial Services Group, Inc.35$780.00%
Steward Partners Investment Advisory, LLC25$560.00%
CWM, LLC163$00.00%

Sold out (3)

Institutions that held Protalix BioTherapeutics, Inc. at the end of Q2 2025 and filed for Q3 2025 without it.

Institutions that sold out of PLX in Q3 2025
InstitutionShares, Q2 2025Value, Q2 2025
Hillsdale Investment Management Inc.118,100$174.8K
Two Sigma Investments, LP71,537$105.9K
Harel Insurance Investments & Financial Services Ltd.26,000$40.0K